Association of the Estrogen Receptor 1 Polymorphisms rs2046210 and rs9383590 with the Risk, Age at Onset and Prognosis of Breast Cancer

• Published in: Cells (Basel, Switzerland) Vol. 12; no. 4; p. 515
• Main Authors: Miedl, Heidi, Oswald, Denise, Haslinger, Isabella, Gstoettner, Manuela, Wenzl, René, Proestling, Katharina, Schneeberger, Christian, Yotova, Iveta, Schreiber, Martin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04.02.2023; MDPI
• Subjects: Age; Age of Onset; Breast cancer; Breast Neoplasms - genetics; Case-Control Studies; ERα; ESR1; Estrogen; estrogen receptor; Estrogen Receptor alpha - genetics; Estrogen receptors; Estrogens; Female; Genes; Genetic aspects; Genetic diversity; Genetic polymorphisms; Gynecology; Health aspects; Heterozygotes; Homozygotes; Humans; Middle Aged; Obstetrics; Patients; Polymorphism, Single Nucleotide; Population studies; Prognosis; Receptors; Risk factors; single nucleotide polymorphism (SNP); single nucleotide variant (SNV); Therapeutic targets; Austria; ERα; estrogen receptor; rs2046210; single nucleotide polymorphism (SNP); survival; breast cancer; single nucleotide variant (SNV); ESR1; age at onset; rs9383590
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12040515

Estrogen receptor α (ERα), encoded by the gene, is a key prognostic and predictive biomarker firmly established in routine diagnostics and as a therapeutic target of breast cancer, and it has a central function in breast cancer biology. Genetic variants at 6q25.1, containing the gene, were found to be associated with breast cancer susceptibility. The rs2046210 and rs9383590 single nucleotide variants (SNVs) are located in the same putative enhancer region upstream of and were separately identified as candidate causal variants responsible for these associations. Here, both SNVs were genotyped in a hospital-based case-control study of 409 female breast cancer patients and 422 female controls of a Central European (Austrian) study population. We analyzed the association of both SNVs with the risk, age at onset, clinically and molecularly relevant characteristics and prognosis of breast cancer. We also assessed the concordances between both SNVs and the associations of each SNV conditional on the other SNV. The minor alleles of both SNVs were found to be non-significantly associated with an increased breast cancer risk. Significant associations were found in specific subpopulations, particularly in patients with an age younger than 55 years. The minor homozygotes of rs2046210 and the minor homozygotes plus heterozygotes of rs9383590 exhibited a several-years-younger age at onset than the common homozygotes, which was more pronounced in ER-positive and luminal patients. Importantly, the observed associations of each SNV were not consistently nullified upon correction for the other SNV nor upon analyses in common homozygotes for the other SNV. We conclude that both SNVs remain independent candidate causal variants.